According to a new study, the benefactor of health care payments – excluding patients and their caregivers – depends on the treatment and disease.
The study, titled “Insurance Switching and the Mismatch Between the Costs and Benefits of New Technologies,” was conducted by the National Pharmaceutical Council, Analysis Group and Harvard University Professor David Cutler.
According to the NPC, the study analyzed the “disconnect” between a treatment’s short-term impact on a budget, and its “downstream effects” on both payers and society as a whole.
” … The study modeled the impact of short-term versus future payments via a curative gene therapy for a childhood disorder, a highly effective hepatitis C therapy, disease-modifying Alzheimer’s therapy, and cardiovascular disease therapy for both rare and genetic higher risk prior cardiovascular event populations,” the NPC says.
You can read the full study by clicking here.